The European Blood and Marrow Transplantation Textbook for Nurses : : Under the Auspices of EBMT.

• Author: Kenyon, Michelle.
• TeilnehmendeR: Babic, Aleksandra.
• Place / Publishing House: Cham : : Springer International Publishing AG,, 2018.; ©2018.
• Year of Publication: 2018
• Edition: 1st ed.
• Language: English
• Physical Description: 1 online resource (318 pages)

Table of Contents

Intro -- Foreword -- Preface -- Contents -- About the Author -- Brief History of HSCT Nursing: HSCT Nursing Through the Ages and Its Evolution -- Literature -- 1: JACIE and Quality Management in HSCT: Implications for Nursing -- 1.1 Background to JACIE -- 1.2 Preparing for JACIE Accreditation -- 1.2.1 Considerations -- 1.2.2 Implementing a Quality Management System -- 1.3 The JACIE Accreditation Process -- 1.3.1 Start Working with the Standards -- 1.3.2 Application for JACIE Accreditation -- 1.3.3 Arranging the Inspection Date -- 1.3.4 The Inspection -- 1.3.5 The Inspection Report -- 1.3.6 Corrections and Accreditation Award -- 1.3.7 Post JACIE Accreditation -- 1.4 JACIE Standards that Affect Nursing: Clinical and Collection -- 1.4.1 Staffing and Nursing (Table 1.2) -- 1.4.2 Training and Competencies (Tables 1.2 and 1.3) -- 1.4.3 Benefits of Quality Management (Table 1.3) -- 1.4.4 Audits (Table 1.3) -- 1.4.5 Reporting Adverse Events (Table 1.3) -- 1.4.6 Tracking of Collected Products (Table 1.3) -- 1.4.7 Common Deficiencies: 5th Edition of the JACIE Standards -- 1.5 JACIE: Implications on Nursing - The Nurse's Perspective -- 1.5.1 Results of the Survey -- 1.6 Results -- 1.7 Does the JACIE Process Have Any Implications for Nurses? -- 1.7.1 Implications: Staff Nurse's/Junior Nurse's Point of View -- 1.7.2 Implications: Ward Manager's Point of View Can Be Summarised as Follows -- 1.7.3 Implications: Clinical Nurse Specialist's Point of View Can Be Summarised as Follows -- 1.7.4 Implications: Quality Manager's Point of View Can Be Summarised as Follows -- 1.7.5 Implications: Nurse Coordinator's Point of View Can Be Summarised as Follows -- 1.8 Conclusion of the Survey -- 1.9 Discussion Points -- Appendix 1.1. Citations Classified in the Role of the Nurse -- References -- 2: HSCT: How Does It Work?.

2.1 What Nurses Need to Know -- 2.1.1 Introduction -- 2.1.2 Aims of HSCT -- 2.1.3 Outcomes -- 2.1.4 Nursing Considerations -- 2.2 Different Types of HSCT -- 2.2.1 Autologous Haematopoietic Stem Cell Transplantation -- 2.2.2 Allogeneic Stem Cell Transplantation -- 2.2.2.1 Allogeneic Transplantation from HLA-Matched Related Donor (MRD) -- 2.2.2.2 Allogeneic from Unrelated Donor (MUD, MMUD) -- 2.2.2.3 Cord Blood Transplantation -- 2.2.2.4 Haploidentical Transplantation -- 2.2.2.5 Syngeneic Transplantation -- 2.3 The Stem Cell Sources -- 2.3.1 Peripheral Blood Stem Cells -- 2.3.2 Bone Marrow -- 2.3.3 Umbilical Cord Blood -- 2.3.4 HSCT Phases -- 2.3.4.1 Neutropenic Phase -- 2.4 Indications for Transplant in Malignant Disease -- 2.4.1 Indications for Allogeneic HSCT -- 2.4.2 Indications for Autologous HSCT -- 2.5 Indications for Transplant in Non-malignant Diseases in Children -- 2.5.1 Transplant in Primary Immunodeficiencies -- 2.5.2 Severe Combined Immunodeficiencies -- 2.5.3 Non-SCID Primary Immunodeficiencies -- 2.5.4 Newborn Screening -- 2.5.5 Inherited Bone Marrow Failure -- 2.5.6 Inherited Diseases: Inborn Errors of Metabolism -- References -- References for Indications for Transplant in Non-malignant Diseases in Children -- 3: Donor Selection -- 3.1 Introduction -- 3.2 Human Leukocyte Antigens -- 3.3 Eligibility for HLA Typing of Potential Related Donors -- 3.4 Algorithm of Donor Choice and Selection -- 3.4.1 Donor Selection -- 3.4.2 HLA Match -- 3.4.3 Cytomegalovirus (CMV) Status -- 3.4.4 Blood Group -- 3.4.5 Sex Match -- 3.4.6 Parity -- 3.4.7 Age -- 3.4.8 Donor Evaluation -- 3.5 Special Considerations -- 3.5.1 Screening of Elderly Donors -- 3.5.2 Screening of Paediatric Donors -- 3.5.3 Confidentiality -- 3.5.4 Donor Consent and Clearance -- 3.5.5 Stem Cell Source -- References.

4: Transplant Preparation -- 4.1 The Role of Transplant Coordinator -- 4.2 Information and Consent -- 4.3 Information and Consents in the Paediatric Population -- 4.4 Role of Risk Assessment and Co-morbidity Scores -- 4.5 Fertility Preservation -- 4.6 Fertility Preservation in the Paediatric Population -- 4.6.1 Fertility Counselling -- 4.6.2 When? -- 4.6.3 Issues -- 4.6.4 Who? -- 4.6.5 Recommendations on Fertility Preservation for Girls and Young Women with Childhood Cancer -- 4.6.5.1 Menstruating Girls -- 4.6.5.2 All Girls Regardless of Maturational Stage -- 4.6.6 Recommendations on Fertility Preservation for Boys and Young Men with Childhood Cancer -- 4.6.6.1 Pubertal and Post-pubertal Males -- 4.6.6.2 Prepubertal Boys -- 4.6.7 Techniques -- 4.6.8 Fertility Preservation Options for Children and Young Adults with Distinction Between Established and Experimental Options -- 4.6.9 Sexuality in Adolescents and Young Adults -- 4.6.10 Conclusion -- 4.7 Transplant Workup -- 4.8 Venous Access Devices: Principles of Placement and Care -- 4.8.1 Vascular Access Devices -- 4.8.2 Care and Maintenance -- 4.8.3 Flushing and Locking -- 4.8.4 Securement -- 4.8.5 Occlusion -- 4.8.6 CVAD Removal -- 4.8.7 Pre-transplant Disease Assessment -- 4.9 The Advocacy Role of HSCT Nurses -- 4.10 Ethical Dilemmas -- 4.11 Ethical Issues in Minors -- References -- 5: Cell Source and Apheresis -- 5.1 Cell Source: Where Do We Get the Cells From? -- 5.1.1 Cell Collection -- 5.2 Mobilization of Stem Cells and Apheresis -- 5.2.1 Cytokines -- 5.2.2 The Role of CD34+ -- 5.2.3 Chemo-mobilization -- 5.2.4 Alternative Mobilization Strategies -- 5.2.5 PBSC Collection by Apheresis -- 5.3 Vascular Access -- 5.4 Adverse Reactions -- 5.4.1 Citrate Toxicity -- 5.4.2 Treatment -- 5.4.3 Hypovolemia -- 5.4.4 Risk Factors -- 5.4.5 Preventative Measures.

5.4.6 Clinical Manifestations -- 5.4.7 Treatment -- 5.4.8 Thrombocytopenia -- 5.4.9 Treatment -- 5.5 Patient Assessment and Preparation -- 5.5.1 Medical Assessment -- 5.5.2 Patient Education -- 5.5.3 Donor Assessment and Preparation -- 5.6 Quality in Apheresis -- 5.6.1 Training and Competencies -- 5.7 Cell Source and Apheresis in the Pediatric Population -- 5.7.1 Introduction -- 5.7.2 Apheresis in Pediatric Population -- 5.7.3 Key Differences: Pediatric vs Adult -- 5.7.4 Ethical Dilemmas -- 5.7.5 Psychosocial Risks and Benefits -- References -- 6: Principles of Conditioning Therapy and Cell Infusion -- 6.1 Conditioning -- 6.2 Chemotherapy -- 6.2.1 Combination Chemotherapy -- 6.2.2 Cycles and Scheduling -- 6.2.3 Modes of Administration -- 6.2.4 Side Effects and Nursing Implications -- 6.3 Radiotherapy -- 6.3.1 Total Body Irradiation -- 6.3.2 Side Effects and Nursing Implications -- 6.4 Immunotherapy -- 6.4.1 Cancer Immunotherapy -- 6.4.1.1 Immune Checkpoint Blockade -- 6.4.1.2 Immune Cell Therapy -- 6.4.1.3 Therapeutic Antibodies -- 6.4.1.4 Therapeutic Cancer Vaccines -- 6.5 Paediatric Considerations -- 6.5.1 Chemotherapy -- 6.5.2 Total Body Irradiation -- 6.6 Stem Cell Infusion -- 6.6.1 Adverse Reactions -- 6.6.2 Nursing Care: Pre-, During and Post Stem Cell Infusion -- 6.6.2.1 Pre-infusion Assessment -- 6.6.2.2 During Stem Cell Infusion -- 6.6.2.3 Post Stem Cell Infusion -- 6.6.3 JACIE Standards -- References -- Further Reading -- 7: BMT Settings, Infection and Infection Control -- 7.1 Introduction -- 7.2 Viral Infections -- 7.2.1 Cytomegalovirus -- 7.2.1.1 Introduction -- 7.2.1.2 Presentation -- 7.2.1.3 Diagnosis -- 7.2.1.4 Monitoring and Surveillance -- 7.2.1.5 Treatment -- 7.2.2 EBV -- 7.2.2.1 Introduction -- 7.2.2.2 Presentation and Manifestations -- 7.2.2.3 Diagnosis -- 7.2.2.4 Monitoring.

7.2.2.5 Treatment -- 7.2.3 HHV6 -- 7.2.3.1 Introduction -- 7.2.3.2 Risk -- 7.2.3.3 Presentation -- 7.2.3.4 Diagnosis -- 7.2.3.5 Treatment -- 7.2.4 Pneumocystis jirovecii -- 7.2.4.1 Introduction -- 7.2.4.2 Risk Factors -- 7.2.4.3 Presentation -- 7.2.4.4 Diagnosis -- 7.2.4.5 Treatment -- 7.2.5 Varicella Zoster Virus -- 7.2.5.1 Introduction -- 7.2.5.2 Risk Factors -- 7.2.5.3 Presentation -- 7.2.5.4 Diagnosis -- 7.2.5.5 Treatment -- 7.2.6 Adenovirus -- 7.2.6.1 Introduction -- 7.2.6.2 Risk Factors -- 7.2.6.3 Presentation -- 7.2.6.4 Diagnosis -- 7.2.6.5 Treatment -- 7.2.7 Hepatitis B -- 7.2.7.1 Background -- 7.2.7.2 Clinical Features -- 7.2.7.3 Treatment -- 7.2.7.4 Prevention -- 7.2.8 Hepatitis C -- 7.2.8.1 Background -- 7.2.8.2 Clinical Features -- 7.2.8.3 Treatment -- 7.2.8.4 Prevention -- 7.2.9 Emerging Infections (Hepatitis E) -- 7.2.9.1 Background -- 7.2.9.2 Clinical Features -- 7.2.9.3 HEV in Developing Countries -- 7.2.9.4 HEV in Developed Countries -- 7.2.9.5 Treatment -- 7.2.9.6 Prevention -- 7.2.10 Multiply-Resistant Bacteria: Reducing the Spread -- 7.2.10.1 Background -- 7.2.10.2 Contact Precautions -- 7.2.11 Gram-Positive Bacteria -- 7.2.11.1 Enterococci -- 7.2.11.2 Vancomycin-Resistant Enterococci (VRE) -- 7.2.11.3 Coagulase-Negative Staphylococcus (CNS) -- 7.2.11.4 Staphylococcus aureus -- 7.2.11.5 MRSA -- 7.2.11.6 Streptococcus viridans -- 7.2.11.7 Streptococcus pneumoniae -- 7.2.12 Gram-Negative Bacteria -- 7.2.12.1 Enterobacteriaceae -- 7.2.12.2 Klebsiella pneumoniae -- 7.2.12.3 Carbapenemase-Producing Klebsiella pneumoniae -- 7.2.12.4 Pseudomonas aeruginosa -- 7.2.12.5 Acinetobacter baumannii -- 7.2.13 Clostridium difficile -- 7.2.13.1 Background -- 7.2.13.2 Infection Control Management -- 7.2.13.3 Treatment -- 7.2.13.4 Faecal Microbiota Transplant.

7.3 BMT Setting, Infection and Infection Control.